Frequencies of VKORC1-1639G>A and rs397509427 in Patients on Warfarin and Healthy Syrian Subjects

Background. Vitamin K epoxide reductase complex subunit 1 (VKORC1) gene encodes a key enzyme with multiple cellular activities, namely, the reduction of vitamin K to its active form. VKORC1-1639G>A (rs9923231) is a common single nucleotide polymorphism with a crucial impact on warfarin dosing and...

Full description

Saved in:
Bibliographic Details
Main Authors: Yara Altawil, Lama A. Youssef
Format: Article
Language:English
Published: Wiley 2023-01-01
Series:Cardiovascular Therapeutics
Online Access:http://dx.doi.org/10.1155/2023/8898922
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849308767860031488
author Yara Altawil
Lama A. Youssef
author_facet Yara Altawil
Lama A. Youssef
author_sort Yara Altawil
collection DOAJ
description Background. Vitamin K epoxide reductase complex subunit 1 (VKORC1) gene encodes a key enzyme with multiple cellular activities, namely, the reduction of vitamin K to its active form. VKORC1-1639G>A (rs9923231) is a common single nucleotide polymorphism with a crucial impact on warfarin dosing and possibly other physiological functions. This study aimed at investigating the frequencies of VKORC1-1639G>A alleles and genotypes in Syrian healthy subjects and patients on warfarin for different indications. Methods. A total of 138 individuals were enrolled in this cross-sectional study. Genomic DNA was extracted from both patients on warfarin and healthy subjects, and polymerase chain reaction (PCR) specific amplicons were genotyped via standard sequencing which also allowed the detection of rs397509427. Comparisons of -1639G>A frequency with other populations were drawn. Results. Of 94 patients on warfarin, 53 (56.38%) were with idiopathic venous thromboembolism (VTE). Despite comparable frequencies of the -1639A allele (47% and 50%), the AA and GA genotypes were at disparate frequencies of 93.2% versus 79.8% in the healthy subjects (n=44) versus patients on warfarin, respectively. Carriers of the GG genotype were at a four-fold increased risk of VTE in comparison with those of the AA and GA genotypes (odds ratio OR=4, 95% CI=1.105−13.6, P=0.0469). All study subjects were wild-type for the rs397509427 variant. Conclusions. Our results prove a high -1639A prevalence in Syrian healthy subjects and patients on warfarin at frequencies comparable to other Mediterranean and Middle Eastern populations. The A allele carriers are at a lower VTE risk, whereas a global prevalence gradient of the G allele is suggested to be associated with VTE risk.
format Article
id doaj-art-1b659227376e4441a134aa40fea5b2cf
institution Kabale University
issn 1755-5922
language English
publishDate 2023-01-01
publisher Wiley
record_format Article
series Cardiovascular Therapeutics
spelling doaj-art-1b659227376e4441a134aa40fea5b2cf2025-08-20T03:54:23ZengWileyCardiovascular Therapeutics1755-59222023-01-01202310.1155/2023/8898922Frequencies of VKORC1-1639G>A and rs397509427 in Patients on Warfarin and Healthy Syrian SubjectsYara Altawil0Lama A. Youssef1Department of Pharmaceutics and Pharmaceutical TechnologyDepartment of Pharmaceutics and Pharmaceutical TechnologyBackground. Vitamin K epoxide reductase complex subunit 1 (VKORC1) gene encodes a key enzyme with multiple cellular activities, namely, the reduction of vitamin K to its active form. VKORC1-1639G>A (rs9923231) is a common single nucleotide polymorphism with a crucial impact on warfarin dosing and possibly other physiological functions. This study aimed at investigating the frequencies of VKORC1-1639G>A alleles and genotypes in Syrian healthy subjects and patients on warfarin for different indications. Methods. A total of 138 individuals were enrolled in this cross-sectional study. Genomic DNA was extracted from both patients on warfarin and healthy subjects, and polymerase chain reaction (PCR) specific amplicons were genotyped via standard sequencing which also allowed the detection of rs397509427. Comparisons of -1639G>A frequency with other populations were drawn. Results. Of 94 patients on warfarin, 53 (56.38%) were with idiopathic venous thromboembolism (VTE). Despite comparable frequencies of the -1639A allele (47% and 50%), the AA and GA genotypes were at disparate frequencies of 93.2% versus 79.8% in the healthy subjects (n=44) versus patients on warfarin, respectively. Carriers of the GG genotype were at a four-fold increased risk of VTE in comparison with those of the AA and GA genotypes (odds ratio OR=4, 95% CI=1.105−13.6, P=0.0469). All study subjects were wild-type for the rs397509427 variant. Conclusions. Our results prove a high -1639A prevalence in Syrian healthy subjects and patients on warfarin at frequencies comparable to other Mediterranean and Middle Eastern populations. The A allele carriers are at a lower VTE risk, whereas a global prevalence gradient of the G allele is suggested to be associated with VTE risk.http://dx.doi.org/10.1155/2023/8898922
spellingShingle Yara Altawil
Lama A. Youssef
Frequencies of VKORC1-1639G>A and rs397509427 in Patients on Warfarin and Healthy Syrian Subjects
Cardiovascular Therapeutics
title Frequencies of VKORC1-1639G>A and rs397509427 in Patients on Warfarin and Healthy Syrian Subjects
title_full Frequencies of VKORC1-1639G>A and rs397509427 in Patients on Warfarin and Healthy Syrian Subjects
title_fullStr Frequencies of VKORC1-1639G>A and rs397509427 in Patients on Warfarin and Healthy Syrian Subjects
title_full_unstemmed Frequencies of VKORC1-1639G>A and rs397509427 in Patients on Warfarin and Healthy Syrian Subjects
title_short Frequencies of VKORC1-1639G>A and rs397509427 in Patients on Warfarin and Healthy Syrian Subjects
title_sort frequencies of vkorc1 1639g a and rs397509427 in patients on warfarin and healthy syrian subjects
url http://dx.doi.org/10.1155/2023/8898922
work_keys_str_mv AT yaraaltawil frequenciesofvkorc11639gaandrs397509427inpatientsonwarfarinandhealthysyriansubjects
AT lamaayoussef frequenciesofvkorc11639gaandrs397509427inpatientsonwarfarinandhealthysyriansubjects